Ascendis Pharma A/S

NasdaqGS:ASND

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💻 Telehealth

Location

Denmark

Market Cap

USD 10.63 B

Share Price

USD 175.78

Avg Daily Volume

505,371

Change (1 day)

-0.63%

Change (1 year)

37.49%

Change (YTD)

27.68%

Ascendis Pharma A/S Common Stock Issued for the Trailing 12 Months (TTM) ending December 31, 2024: USD 43.28 M

Ascendis Pharma A/S Common Stock Issued is USD 43.28 M for the Trailing 12 Months (TTM) ending December 31, 2024, a 291.66% change year over year. Common stock issued is cash received from issuing new shares of the company’s common stock.

Ascendis Pharma A/S Common Stock Issued for the Trailing 12 Months (TTM) ending December 31, 2023 was USD 11.05 M.
Ascendis Pharma A/S Common Stock Issued for the Trailing 12 Months (TTM) ending December 31, 2022 was USD 0.00, a -100.00% change year over year.
Ascendis Pharma A/S Common Stock Issued for the Trailing 12 Months (TTM) ending December 31, 2021 was USD 451.26 M, a -39.73% change year over year.
Ascendis Pharma A/S Common Stock Issued for the Trailing 12 Months (TTM) ending December 31, 2020 was USD 748.70 M, a 26.09% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Common Stock Issued	Common Stock Repurchased	Free Cash Flow	Operating Cash Flow

NasdaqGS: ASND

Ascendis Pharma A/S

CEO	Mr. Jan Moller Mikkelsen
IPO Date	Jan. 28, 2015
Location	Denmark
Headquarters	Tuborg Boulevard 12
Employees	1,017
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💻 Telehealth

Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.